Phibro Animal Health (NASDAQ:PAHC) Shares Gap Up After Earnings Beat

Phibro Animal Health Corporation (NASDAQ:PAHC)’s stock price gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $36.09, but opened at $39.39. Phibro Animal Health shares last traded at $36.3350, with a volume of 35,419 shares trading hands.

The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.14. The business had revenue of $396.75 million during the quarter, compared to analyst estimates of $381.18 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Wednesday, September 2nd will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, September 2nd. This represents a $0.48 dividend on an annualized basis and a yield of 1.3%. Phibro Animal Health’s dividend payout ratio is currently 20.60%.

Analyst Upgrades and Downgrades

PAHC has been the subject of several research reports. Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Citigroup cut their target price on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Weiss Ratings cut shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. Finally, Wall Street Zen downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Phibro Animal Health has an average rating of “Hold” and an average price target of $42.50.

Institutional Investors Weigh In On Phibro Animal Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. 1620 Investment Advisors Inc. lifted its holdings in Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after purchasing an additional 295 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Phibro Animal Health by 113.2% in the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after purchasing an additional 386 shares during the period. KBC Group NV purchased a new stake in shares of Phibro Animal Health in the first quarter worth $29,000. Rothschild Investment LLC increased its stake in shares of Phibro Animal Health by 2,500.0% in the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after purchasing an additional 1,000 shares in the last quarter. Finally, iSAM Funds UK Ltd bought a new stake in shares of Phibro Animal Health during the 3rd quarter valued at $61,000. 99.34% of the stock is owned by hedge funds and other institutional investors.

Phibro Animal Health Stock Down 0.6%

The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17. The company’s 50-day moving average price is $33.95 and its 200 day moving average price is $42.44. The stock has a market capitalization of $1.45 billion, a P/E ratio of 15.19, a P/E/G ratio of 0.51 and a beta of 0.46.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.